Compare FDX & GSK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FDX | GSK |
|---|---|---|
| Founded | 1971 | 1715 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Air Freight/Delivery Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 76.9B | 108.7B |
| IPO Year | 1997 | 2013 |
| Metric | FDX | GSK |
|---|---|---|
| Price | $334.16 | $52.05 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 21 | 2 |
| Target Price | ★ $376.67 | N/A |
| AVG Volume (30 Days) | 1.5M | ★ 3.8M |
| Earning Date | 03-19-2026 | 04-29-2026 |
| Dividend Yield | 1.49% | ★ 3.40% |
| EPS Growth | ★ 10.35 | N/A |
| EPS | ★ 18.55 | N/A |
| Revenue | ★ $65,450,000,000.00 | N/A |
| Revenue This Year | $7.43 | $6.99 |
| Revenue Next Year | $4.96 | $4.19 |
| P/E Ratio | ★ $18.01 | $32.75 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $221.31 | $38.63 |
| 52 Week High | $413.87 | $61.70 |
| Indicator | FDX | GSK |
|---|---|---|
| Relative Strength Index (RSI) | 62.64 | 50.33 |
| Support Level | $303.61 | $51.55 |
| Resistance Level | $343.53 | $51.79 |
| Average True Range (ATR) | 7.77 | 0.78 |
| MACD | 1.42 | 0.10 |
| Stochastic Oscillator | 82.08 | 66.98 |
FedEx pioneered overnight delivery in 1973 and remains the world's largest express package provider. Following the June 2026 spinoff of FedEx Freight (less-than-truckload shipping), the firm's Federal Express segment-which houses the core package delivery operations-makes up more than 95% of total revenue (previously 87%). The remainder stems from other services, including FedEx Office, which provides document production/shipping, and FedEx Logistics, which provides global forwarding. FedEx acquired Dutch parcel delivery firm TNT Express in 2016, boosting its presence across Europe. TNT was previously the fourth-largest global parcel delivery provider.
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.